Copyright © Inderes 2011 - present. All rights reserved.

Oncopeptides

1.498

 

SEK

 

+0.67 %

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

2 following
+0.67%
+0.13%
-28.15%
-31.75%
-45.53%
-72.56%
-75.89%
-83.67%
-98.17%
-95.11%
www.oncopeptides.com/en/investors

Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.

Revenue
35.22M
EBIT %
-719.62 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ONCO
Daily low / high price
1.49 / 1.586 SEK
Market cap
322.35M SEK
Turnover
97.48K SEK
Volume
65K

Latest videos

Oncopeptides, Audiocast with teleconference, Q3'24
2024-11-07
Oncopeptides, Audiocast with teleconference, Q2'24
2024-08-14
Oncopeptides, Audiocast with teleconference, Q1'24
2024-05-30

Financial calendar

Annual report
2025-02-27
Interim report
2025-05-08
General meeting
2025-05-22
Interim report
2025-08-21
Interim report
2025-11-05

Major Owners
Source: Millistream Market Data AB

OwnerCapitalVotes
HealthCap VIII L.P.12.7 %12.9 %
Avanza Pension7.5 %7.7 %
HealthCap VI L.P.6.6 %6.7 %
Redmile Group LLC6.5 %6.6 %
Nordnet Pensionsförsäkring4.5 %4.6 %
Handelsbanken Fonder2.5 %2.5 %
Oncopeptides AB1.8 %0.2 %
Jakob Lindberg0.9 %0.9 %
Johan Zetterstedt0.7 %0.7 %
Login in to make your own estimates and see other investors estimates.
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account